Acetyl-l-carnitine and oxfenicine on cardiac pumping mechanics in streptozotocin-induced diabetes in male Wistar rats. 2013

Chih-Hsien Wang, and Shoei-Shen Wang, and Wen-Je Ko, and Yih-Sharng Chen, and Chun-Yi Chang, and Ru-Wen Chang, and Kuo-Chu Chang
Department of Surgery, National Taiwan University Hospital, Taipei, Taiwan.

BACKGROUND In the treatment of patients with diabetes, one objective is an improvement of cardiac metabolism to alleviate the left ventricular (LV) function. For this study, we compared the effects of acetyl-l-carnitine (one of the carnitine derivatives) and of oxfenicine (a carnitine palmitoyltransferase-1 inhibitor) on cardiac pumping mechanics in streptozotocin-induced diabetes in male Wistar rats, with a particular focus on the pressure-flow-volume relationship. METHODS Diabetes was induced by a single tail vein injection of 55 mg kg(-1) streptozotocin. The diabetic animals were treated on a daily basis with either acetyl-L-carnitine (1 g L(-1) in drinking water) or oxfenicine (150 mg kg(-1) by oral gavage) for 8 wk. They were also compared with untreated age-matched diabetic controls. LV pressure and ascending aortic flow signals were recorded to calculate the maximal systolic elastance (E max) and the theoretical maximum flow (Q max). Physically, E max reflects the contractility of the myocardium as an intact heart, whereas Q max has an inverse relationship with the LV internal resistance. RESULTS When comparing the diabetic rats with their age-matched controls, the cardiodynamic condition was characterized by a decline in E max associated with the unaltered Q max. Acetyl-l-carnitine (but not oxfenicine) had reduced cardiac levels of malondialdehyde in these insulin-deficient animals. However, treating with acetyl-l-carnitine or oxfenicine resulted in an increase in E max, which suggests that these 2 drugs may protect the contractile status from deteriorating in the diabetic heart. By contrast, Q max showed a significant fall after administration of oxfenicine, but not with acetyl-L-carnitine. The decrease in Q max corresponded to an increase in total vascular resistance when treated with oxfenicine. CONCLUSIONS Acetyl-l-carnitine, but not oxfencine, optimizes the integrative nature of cardiac pumping mechanics by preventing the diabetes-induced deterioration in myocardial intrinsic contractility associated with unaltered LV internal resistance.

UI MeSH Term Description Entries
D008297 Male Males
D009200 Myocardial Contraction Contractile activity of the MYOCARDIUM. Heart Contractility,Inotropism, Cardiac,Cardiac Inotropism,Cardiac Inotropisms,Contractilities, Heart,Contractility, Heart,Contraction, Myocardial,Contractions, Myocardial,Heart Contractilities,Inotropisms, Cardiac,Myocardial Contractions
D003921 Diabetes Mellitus, Experimental Diabetes mellitus induced experimentally by administration of various diabetogenic agents or by PANCREATECTOMY. Alloxan Diabetes,Streptozocin Diabetes,Streptozotocin Diabetes,Experimental Diabetes Mellitus,Diabete, Streptozocin,Diabetes, Alloxan,Diabetes, Streptozocin,Diabetes, Streptozotocin,Streptozocin Diabete
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D005998 Glycine A non-essential amino acid. It is found primarily in gelatin and silk fibroin and used therapeutically as a nutrient. It is also a fast inhibitory neurotransmitter. Aminoacetic Acid,Glycine, Monopotassium Salt,Glycine Carbonate (1:1), Monosodium Salt,Glycine Carbonate (2:1), Monolithium Salt,Glycine Carbonate (2:1), Monopotassium Salt,Glycine Carbonate (2:1), Monosodium Salt,Glycine Hydrochloride,Glycine Hydrochloride (2:1),Glycine Phosphate,Glycine Phosphate (1:1),Glycine Sulfate (3:1),Glycine, Calcium Salt,Glycine, Calcium Salt (2:1),Glycine, Cobalt Salt,Glycine, Copper Salt,Glycine, Monoammonium Salt,Glycine, Monosodium Salt,Glycine, Sodium Hydrogen Carbonate,Acid, Aminoacetic,Calcium Salt Glycine,Cobalt Salt Glycine,Copper Salt Glycine,Hydrochloride, Glycine,Monoammonium Salt Glycine,Monopotassium Salt Glycine,Monosodium Salt Glycine,Phosphate, Glycine,Salt Glycine, Monoammonium,Salt Glycine, Monopotassium,Salt Glycine, Monosodium
D006321 Heart The hollow, muscular organ that maintains the circulation of the blood. Hearts
D006439 Hemodynamics The movement and the forces involved in the movement of the blood through the CARDIOVASCULAR SYSTEM. Hemodynamic
D000108 Acetylcarnitine An acetic acid ester of CARNITINE that facilitates movement of ACETYL COA into the matrices of mammalian MITOCHONDRIA during the oxidation of FATTY ACIDS. Acetyl Carnitine,Medosan,Acetyl-L-Carnitine,Acetylcarnitine, (R)-Isomer,Alcar,Branigen,Levocarnitine Acetyl,Acetyl L Carnitine,Carnitine, Acetyl
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000975 Antioxidants Naturally occurring or synthetic substances that inhibit or retard oxidation reactions. They counteract the damaging effects of oxidation in animal tissues. Anti-Oxidant,Antioxidant,Antioxidant Activity,Endogenous Antioxidant,Endogenous Antioxidants,Anti-Oxidant Effect,Anti-Oxidant Effects,Anti-Oxidants,Antioxidant Effect,Antioxidant Effects,Activity, Antioxidant,Anti Oxidant,Anti Oxidant Effect,Anti Oxidant Effects,Anti Oxidants,Antioxidant, Endogenous,Antioxidants, Endogenous

Related Publications

Chih-Hsien Wang, and Shoei-Shen Wang, and Wen-Je Ko, and Yih-Sharng Chen, and Chun-Yi Chang, and Ru-Wen Chang, and Kuo-Chu Chang
November 2010, European journal of clinical investigation,
Chih-Hsien Wang, and Shoei-Shen Wang, and Wen-Je Ko, and Yih-Sharng Chen, and Chun-Yi Chang, and Ru-Wen Chang, and Kuo-Chu Chang
October 1999, General physiology and biophysics,
Chih-Hsien Wang, and Shoei-Shen Wang, and Wen-Je Ko, and Yih-Sharng Chen, and Chun-Yi Chang, and Ru-Wen Chang, and Kuo-Chu Chang
June 2008, British journal of pharmacology,
Chih-Hsien Wang, and Shoei-Shen Wang, and Wen-Je Ko, and Yih-Sharng Chen, and Chun-Yi Chang, and Ru-Wen Chang, and Kuo-Chu Chang
March 1993, Arzneimittel-Forschung,
Chih-Hsien Wang, and Shoei-Shen Wang, and Wen-Je Ko, and Yih-Sharng Chen, and Chun-Yi Chang, and Ru-Wen Chang, and Kuo-Chu Chang
October 2016, Archives of medical research,
Chih-Hsien Wang, and Shoei-Shen Wang, and Wen-Je Ko, and Yih-Sharng Chen, and Chun-Yi Chang, and Ru-Wen Chang, and Kuo-Chu Chang
June 2002, Diabetes research and clinical practice,
Chih-Hsien Wang, and Shoei-Shen Wang, and Wen-Je Ko, and Yih-Sharng Chen, and Chun-Yi Chang, and Ru-Wen Chang, and Kuo-Chu Chang
February 2022, Environmental science and pollution research international,
Chih-Hsien Wang, and Shoei-Shen Wang, and Wen-Je Ko, and Yih-Sharng Chen, and Chun-Yi Chang, and Ru-Wen Chang, and Kuo-Chu Chang
December 2011, Journal of physiology and biochemistry,
Chih-Hsien Wang, and Shoei-Shen Wang, and Wen-Je Ko, and Yih-Sharng Chen, and Chun-Yi Chang, and Ru-Wen Chang, and Kuo-Chu Chang
September 1998, European journal of pharmacology,
Chih-Hsien Wang, and Shoei-Shen Wang, and Wen-Je Ko, and Yih-Sharng Chen, and Chun-Yi Chang, and Ru-Wen Chang, and Kuo-Chu Chang
December 2020, Journal of diabetes and metabolic disorders,
Copied contents to your clipboard!